NCT03973918View on ClinicalTrials.gov

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

October 1, 2023

Conditions
High Grade GliomaBRAF V600EBRAF V600KAnaplastic AstrocytomaAnaplastic Pleomorphic XanthoastrocytomaGliosarcomaGlioblastoma
Interventions
DRUG

Encorafenib

450mg QD 28 day cycle

DRUG

Binimetinib

45mg BID 28 day cycle

BIOLOGICAL

Research Bloods

Baseline; pre-cycle 3; Pre-cycle 7; off Treatment

BIOLOGICAL

Tumor Tissue

at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides

Trial Locations (3)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27157

Wake Forest University Comprehensive Cancer Center, Winston-Salem

35294-3410

UAB Comprehensive Cancer Center, Birmingham

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03973918 - Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG | Biotech Hunter | Biotech Hunter